Home > Companies > Myralis Pharma

Myralis Pharma

Total dedication to life Innovative and modern in the pharmaceutical sector, the goal to be achieved is in line with what we propose to our clients and partners: always look forward. The reason? The health of thousands of people. Pioneering, Excellence and Technology in our Brands of Success. With a highly qualified Research and Development team, we are able to work together with our physicians, launching pioneering brands in the market. Our growth gives us the certainty of the path and enthusiasm to move forward. That is why we have evolved at a fast and constant pace, delivering innovative medicines not only for our own line but also for a network of partners.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

International Conference on Drug Discovery and Development

1232nd International Conference on Medical, Biological and Pharmaceutical Sciences

2022 ISPE Facilities of the Future Conference

13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

32nd Annual European Pharma Congress

2nd International Conference On Pharmaceutical Research And Drug Discovery

Related News

PRACTICE MANAGEMENT

CITIUS PHARMACEUTICALS RECEIVES FDA RESPONSE AND GUIDANCE TO PRE-IND CONSULTATION SUBMISSION FOR MINO-WRAP

Citius Pharmaceutical | December 10, 2020

Citius Pharmaceuticals, Inc. ("Citius" or the "Organization") (Nasdaq: CTXR), a strength drug organization zeroed in on creating and commercializing basic consideration drug items, declared its receipt of a composed reaction and direction from the U.S. Food and Drug Administration (FDA) Division of Anti-Infective Products to the Company's Pre-Investigational New Drug (Pre-IND) meeting demand for its Mino-Wrap preparation bundle. Through its worldwide permit concurrence wi...

PHARMACY MARKET

STEVANATO GROUP ANNOUNCES EXPANSION OF CORPORATE HEADQUARTERS

Stevanato Group | November 18, 2021

Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the expansion of its corporate headquarters with the construction of a new facility in Piombino Dese, Italy to advance operations and growth of the Company. The new 6,750 square meter facility is expected to support the optimization of Stevanato Group’s industrial footprint, with about 2,500 square m...

PHARMACY MARKET

CSTONE AND LEGOCHEM BIOSCIENCES ENTER GLOBAL LICENSING AGREEMENT FOR NEW ANTIBODY DRUG CONJUGATE

CStone | October 29, 2020

CStone Pharmaceuticals declared today a permitting concurrence with Lego Chem Bio sciences, Inc, for the turn of events and commercialization of LCB71, a likely first-in-class/top tier immunizer drug form ("ADC"). Under the understanding, CStone gets the selective worldwide option to lead advancement and commercialization of LCB71 outside the Republic of Korea. LCB will get a forthright installment of US$10 million, and up to US$353.5 million in combined achievement inst...

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

BioSpace | March 02, 2020

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

PRACTICE MANAGEMENT